eIF2B Prodrug Modulators for Integrated Stress Response Attenuation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for diseases related to the integrated stress response (ISR) pathway, such as neurodegenerative diseases and cancers, are inadequate in modulating eIF2B activity, leading to insufficient attenuation of translation initiation and cellular stress.
Innovation Solution
Development of compounds represented by Formula (I) that modulate eIF2B activity, enhancing its GEF activity and stabilizing the eIF2B dimer conformation to attenuate the ISR pathway, thereby treating diseases like neurodegenerative diseases, cancers, and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat diseases related to the ISR pathway, then treatment is provided, but modulation of eIF2B activity is inadequate, leading to insufficient attenuation of translation initiation and cellular stress
Solution Approach 1:
The patent applies parameter changes by developing compounds that specifically modulate eIF2B activity parameters. The compounds alter the functional parameters of eIF2B (GEF activity, dimer conformation stability) to achieve effective ISR pathway attenuation, transitioning from inadequate modulation to effective modulation of these specific biological parameters
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to bridge the gap between current therapies and the desired therapeutic effect. These compounds act as mediators that specifically interact with eIF2B to enhance its activity, thereby amplifying the attenuation of the ISR pathway and providing the missing therapeutic effectiveness
2Productivity
If eIF2α is phosphorylated to attenuate translation, then translation initiation is reduced, but the effect is insufficient without adequate eIF2B modulation
Solution Approach 1:
The patent applies preliminary action by enhancing eIF2B activity before or concurrent with eIF2α phosphorylation. By pre-modulating eIF2B to be in a more active state through compound treatment, the system prepares the GEF to more effectively compete with phosphorylated eIF2, thereby amplifying the translation initiation attenuation effect when stress occurs
Solution Approach 2:
The patent implements a feedback mechanism where enhanced eIF2B activity responds to and counteracts the effects of eIF2α phosphorylation. The compounds create a feedback loop where increased eIF2B activity dynamically compensates for reduced ternary complex formation, thereby improving cellular stress coping while maintaining controlled translation attenuation
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.